Hims Hers Health is trading 5.46% up now at $31.32 after rebounding from losses tied to the FTC lawsuit.
- The FTC alleges privacy violations, deceptive billing, and difficult subscription cancellations; Hims & Hers denies wrongdoing and plans to defend itself.
- Broader risk appetite supports the move, with the Nasdaq Composite up 0.91% as investors respond to weaker July employment data and increased Federal Reserve rate-cut expectations.